Rigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients

First SYK inhibitor for the treatment of adult chronic ITP SOUTH SAN FRANCISCO, Calif., Oct. 11, 2018 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the European Medicines Agency (EMA) has v... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, fostamatinib, TAVALISSE, thrombocytopenia

https://salesandmarketingnetwork.com/news_release_bs.html?ID=2044424

Source: HSMN NewsFeed - October 11, 2018 Category: Pharmaceuticals Source Type: news

More News: European Medicines Agency (EMA) | Marketing | Pharmaceuticals | Thrombocytopenia